Vivoryon Therapeutics N.V. (VVY.AS)
EUR 1.97
(0.71%)
EUR 1.97
(0.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -28.35 Million EUR | -0.67% |
| 2022 | -28.17 Million EUR | -129.18% |
| 2021 | -12.03 Million EUR | 20.35% |
| 2020 | -16.34 Million EUR | -106.49% |
| 2019 | -7.62 Million EUR | 0.23% |
| 2018 | -7.67 Million EUR | 21.86% |
| 2017 | -9.85 Million EUR | 28.37% |
| 2016 | -13.68 Million EUR | -2.85% |
| 2015 | -13.33 Million EUR | -19.76% |
| 2014 | -11.17 Million EUR | -19.78% |
| 2013 | -9.33 Million EUR | 8.37% |
| 2012 | -10.18 Million EUR | 26.11% |
| 2011 | -13.77 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -13.76 Million EUR | 0.0% |
| 2023 FY | - EUR | -0.67% |
| 2023 Q2 | -10.61 Million EUR | 0.0% |
| 2023 Q4 | -17.5 Million EUR | 0.0% |
| 2022 Q4 | -15.67 Million EUR | 0.0% |
| 2022 FY | - EUR | -129.18% |
| 2022 Q2 | -13.29 Million EUR | 0.0% |
| 2021 Q4 | -931 Thousand EUR | 0.0% |
| 2021 Q2 | -11.71 Million EUR | 0.0% |
| 2021 FY | - EUR | 20.35% |
| 2020 Q4 | -8.41 Million EUR | 0.0% |
| 2020 FY | - EUR | -106.49% |
| 2020 Q2 | -7.45 Million EUR | 0.0% |
| 2019 Q4 | -4.62 Million EUR | 0.0% |
| 2019 Q2 | -3.06 Million EUR | 0.0% |
| 2019 FY | - EUR | 0.23% |
| 2018 Q2 | -4.12 Million EUR | 0.0% |
| 2018 FY | - EUR | 21.86% |
| 2018 Q4 | -3.55 Million EUR | 0.0% |
| 2017 Q2 | -6.19 Million EUR | 0.0% |
| 2017 FY | - EUR | 28.37% |
| 2017 Q4 | -3.66 Million EUR | 0.0% |
| 2016 Q4 | -7.71 Million EUR | 0.0% |
| 2016 FY | - EUR | -2.85% |
| 2016 Q2 | -5.96 Million EUR | 0.0% |
| 2015 Q4 | -7.18 Million EUR | 0.0% |
| 2015 FY | - EUR | -19.76% |
| 2015 Q2 | -6.14 Million EUR | 0.0% |
| 2014 Q4 | -7.49 Million EUR | 0.0% |
| 2014 FY | - EUR | -19.78% |
| 2014 Q2 | -3.67 Million EUR | 0.0% |
| 2013 Q4 | -4.68 Million EUR | -97.09% |
| 2013 Q3 | -2.37 Million EUR | 48.99% |
| 2013 Q2 | -4.65 Million EUR | -96.04% |
| 2013 FY | - EUR | 8.37% |
| 2013 Q1 | -2.37 Million EUR | 0.0% |
| 2012 Q2 | -4.34 Million EUR | 0.0% |
| 2012 Q3 | -4.34 Million EUR | 0.0% |
| 2012 Q4 | -2.37 Million EUR | 45.31% |
| 2012 FY | - EUR | 26.11% |
| 2012 Q1 | -4.34 Million EUR | 0.0% |
| 2011 Q3 | -3.95 Million EUR | 0.0% |
| 2011 Q4 | -4.34 Million EUR | -9.75% |
| 2011 Q2 | -3.95 Million EUR | 0.0% |
| 2011 Q1 | -3.95 Million EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2010 Q4 | -3.95 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -761.793% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 78.715% |
| Adocia SA | -22.73 Million EUR | -24.727% |
| Aelis Farma SA | -6.34 Million EUR | -346.715% |
| Biophytis S.A. | -13.8 Million EUR | -105.397% |
| Advicenne S.A. | -6.24 Million EUR | -354.084% |
| genOway Société anonyme | 6.35 Million EUR | 546.451% |
| IntegraGen SA | -52.5 Thousand EUR | -53902.628% |
| Medesis Pharma S.A. | -3.84 Million EUR | -637.421% |
| Neovacs S.A. | -8.44 Million EUR | -235.556% |
| NFL Biosciences SA | -4.04 Million EUR | -600.195% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 39191.41% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -886.713% |
| Sensorion SA | -22.31 Million EUR | -27.065% |
| Theranexus Société Anonyme | -7.38 Million EUR | -283.811% |
| TME Pharma N.V. | -5.07 Million EUR | -459.01% |
| Valbiotis SA | -6.95 Million EUR | -307.664% |
| TheraVet SA | -517.33 Thousand EUR | -5380.577% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -49.889% |
| argenx SE | -199.5 Million EUR | 85.788% |
| BioSenic S.A. | -6.79 Million EUR | -317.201% |
| Celyad Oncology SA | -7.76 Million EUR | -265.233% |
| DBV Technologies S.A. | -79.53 Million EUR | 64.35% |
| Galapagos NV | 51.03 Million EUR | 155.554% |
| Genfit S.A. | -28.05 Million EUR | -1.077% |
| GeNeuro SA | -14.31 Million EUR | -98.028% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -89.272% |
| Innate Pharma S.A. | -7.57 Million EUR | -274.149% |
| Inventiva S.A. | -101.84 Million EUR | 72.161% |
| MaaT Pharma SA | -19.74 Million EUR | -43.632% |
| MedinCell S.A. | -20.04 Million EUR | -41.44% |
| Nanobiotix S.A. | -34.01 Million EUR | 16.655% |
| Onward Medical N.V. | -35.23 Million EUR | 19.529% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -539.538% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -21.865% |
| Oxurion NV | -16.72 Million EUR | -69.484% |
| Pharming Group N.V. | 4.98 Million EUR | 669.227% |
| Poxel S.A. | -12.17 Million EUR | -132.802% |
| GenSight Biologics S.A. | -21.73 Million EUR | -30.479% |
| Transgene SA | -27.02 Million EUR | -4.918% |
| Financière de Tubize SA | 184.57 Thousand EUR | 15461.568% |
| UCB SA | 1.26 Billion EUR | 102.234% |
| Valneva SE | -64.51 Million EUR | 56.053% |